Literature DB >> 3291454

Application of recombinant DNA techniques in the development of viral vaccines.

K Murray1.   

Abstract

The wide repertoire of methods developed for the construction and manipulation of recombinant DNA molecules enable viral genomes to be cloned and their genes expressed, in whole or in part, in microbial or animal cells in culture. This provides a ready source of many viral components that are otherwise difficult to obtain and in some cases were previously unknown. Although immediate applications for vaccine development have concentrated principally upon envelope proteins, the immunological importance of other viral components is being increasingly recognized. Hepatitis B virus is used here to exemplify the application of recombinant DNA technology to the development of subunit vaccines and to illustrate their value in studies of other viral proteins with particular emphasis on the role of the core antigen in providing protection against viral infection and hence its potential in vaccine development.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3291454     DOI: 10.1016/s0264-410x(88)80022-7

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  4 in total

1.  Immunogenicity of peptide fusions to hepatitis B virus core antigen.

Authors:  S J Stahl; K Murray
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

2.  Epitope mapping of neutralizing monoclonal antibodies against duck hepatitis B virus.

Authors:  R C Cheung; W S Robinson; P L Marion; H B Greenberg
Journal:  J Virol       Date:  1989-06       Impact factor: 5.103

3.  The concentration of carbon source in the medium affects the quality of virus-like particles of human papillomavirus type 16 produced in Saccharomyces cerevisiae.

Authors:  Hyoung Jin Kim; Yingji Jin; Hong-Jin Kim
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

Review 4.  Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development.

Authors:  Natasha Kushnir; Stephen J Streatfield; Vidadi Yusibov
Journal:  Vaccine       Date:  2012-11-06       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.